Cekic O, Batman C, Yasar U, Basci N E, Bozkurt A, Kayaalp S O
Department of Vitreoretinal Surgery, SSK Ankara Eye Hospital, Turkey.
Retina. 1998;18(6):521-5. doi: 10.1097/00006982-199806000-00005.
To determine aqueous and vitreous humor ofloxacin levels following oral and topical application of ofloxacin in patients with noninflamed cornea and intact crystalline lens, and to compare the drug levels provided by each route.
Twenty-six patients undergoing pars plana vitrectomy for various ocular pathologies were divided into two groups. Fourteen patients received two drops of 0.3% ophthalmic solution of ofloxacin every 30 minutes for 3 hours and every 60 minutes for the next 3 hours, and 12 patients received a single oral dose of 400 mg ofloxacin 8 hours before surgery. The aqueous and vitreous humor samples were simultaneously collected after oral or topical administration during pars plana vitrectomy to assess penetration of the drug. Samples were assayed for ofloxacin concentrations by a previously described method using high-performance liquid chromatography.
The aqueous and vitreous humor levels of ofloxacin were 1.54 +/- 0.27 microg/mL (mean +/- standard error) and 1.77 +/- 0.24 microg/mL after oral and 1.44 +/- 0.24 microg/mL and 0.37 +/- 0.05 microg/mL after topical ofloxacin administration, respectively. Aqueous humor levels were not statistically different following oral or topical administration (P > 0.8). However, vitreous level of the drug after oral administration was significantly higher than that after topical administration (P < 0.001).
Ocular bioavailability of ofloxacin in aqueous humor after oral and topical administration is similar when the drug is applied as described. Penetration of ofloxacin into vitreous humor is less than that into aqueous humor following topical application. The aqueous humor levels of ofloxacin via both routes and the vitreous level of the drug after oral route exceed the minimum inhibitory concentrations for certain bacterial species that frequently cause intraocular infection.
测定非炎症性角膜且晶状体完整的患者口服和局部应用氧氟沙星后房水和玻璃体内的氧氟沙星水平,并比较每种给药途径所提供的药物水平。
26例因各种眼部疾病接受玻璃体切除术的患者被分为两组。14例患者每30分钟滴入两滴0.3%的氧氟沙星眼药水,共3小时,随后3小时每60分钟滴入两滴;12例患者在手术前8小时口服400mg氧氟沙星。在玻璃体切除术期间口服或局部给药后,同时采集房水和玻璃体液样本以评估药物的渗透情况。使用高效液相色谱法,通过先前描述的方法测定样本中的氧氟沙星浓度。
口服氧氟沙星后,房水和玻璃体内的氧氟沙星水平分别为1.54±0.27μg/mL(平均值±标准误差)和1.77±0.24μg/mL;局部应用氧氟沙星后,房水和玻璃体内的氧氟沙星水平分别为1.44±0.24μg/mL和0.37±0.05μg/mL。口服或局部给药后房水水平无统计学差异(P>0.8)。然而,口服给药后玻璃体内的药物水平显著高于局部给药后(P<0.001)。
按照所述方法应用药物时,口服和局部应用氧氟沙星后,其在房水中的眼部生物利用度相似。局部应用后,氧氟沙星进入玻璃体液的渗透量低于进入房水的渗透量。两种给药途径的房水氧氟沙星水平以及口服途径后的玻璃体液药物水平均超过某些常见引起眼内感染的细菌种类的最低抑菌浓度。